TT
The startup develops antineoplastic therapeutics using proprietary scaffold redesign and hopping technology, which integrates mechanism of action and chemical design to target previously undruggable cancer pathways. This approach enables drug researchers to screen trillions of molecules for resistance prediction and antibody redesign, enhancing the durability of therapeutic responses.
Updated 3 months ago
Funding
$21.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops antineoplastic therapeutics using proprietary scaffold redesign and hopping technology, which integrates mechanism of action and chemical design to target previously undruggable cancer pathways. This approach enables drug researchers to screen trillions of molecules for resistance prediction and antibody redesign, enhancing the durability of therapeutic responses.